WEKO3
アイテム
{"_buckets": {"deposit": "7ec51a9f-ceed-47b0-8167-b8b06db4c8a7"}, "_deposit": {"created_by": 2, "id": "570", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "570"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00000570", "sets": ["92"]}, "author_link": ["2959", "2958", "2956", "2952", "2954", "2955", "2957", "2953"], "item_3_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2020-03", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "77", "bibliographicPageStart": "71", "bibliographicVolumeNumber": "63", "bibliographic_titles": [{"bibliographic_title": "Acta medica Nagasakiensia"}]}]}, "item_3_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background: Lenvatinib is one of the few therapeutic options available for radioiodine-refractory thyroid cancer. However, the factors that determine the therapeutic outcomes remain unknown.\nMethods: Patients with thyroid carcinoma treated with lenvatinib who had been dead or who had survived for longer than a halfyear\nwere retrospectively compared. We evaluated the clinical parameters when lenvatinib was started, and also studied the tumor volume reduction ratio, the duration until re-growth of the largest metastatic lesion, the thyroglobulin (Tg) reduction rate,and the duration until re-elevation of Tg after lenvatinib between survivors and dead patients.Results: We identified 16 patients, with an average age of 73.1±7.6 yrs and a male-to-female ratio of 5 to 11, who had advanced differentiated thyroid cancer that was treated with lenvatinib. Nine patients had died after 8.9±6.1 months, whereas 7 survived for 13.0±2.0 months after starting lenvatinib. The patients who died were older than the survivors (76.7±6.5 vs. 68.6±6.6 yrs, p=0.03).Malignant pleural effusion (p=0.017) and symptomatic metastatic disease (SMD) (p=0.039) were associated with death in a Kaplan-Meier survival analysis. Age (p=0.012, HR 1.150, CI 1.030-1.320) and SMD (p=0.014, HR 8.069, CI 1.503-61.34) were\nassociated with poor outcome in a multivariate Cox proportional hazard model. The duration until the re-elevation of Tg was\nlonger in survivors than in patients who died (6.43±4.55 vs. 2.17±1.39 months, p=0.025).Conclusions: We identified multiple factors, including SMD, that were related to poor outcomes after lenvatinib treatment. This study suggests that lenvatinib might be started before patients develop SMD.", "subitem_description_type": "Abstract"}]}, "item_3_description_64": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Acta medica Nagasakiensia, 63(2), pp.71-77; 2020", "subitem_description_type": "Other"}]}, "item_3_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagasaki University School of Medicine"}]}, "item_3_source_id_10": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA00508430", "subitem_source_identifier_type": "NCID"}]}, "item_3_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00016055", "subitem_source_identifier_type": "ISSN"}]}, "item_3_text_62": {"attribute_name": "sortkey", "attribute_value_mlt": [{"subitem_text_value": "03"}]}, "item_3_text_63": {"attribute_name": "出版者別言語", "attribute_value_mlt": [{"subitem_text_value": "長崎大学医学部"}]}, "item_3_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Nakashima, Yomi"}], "nameIdentifiers": [{"nameIdentifier": "2952", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ando, Takao"}], "nameIdentifiers": [{"nameIdentifier": "2953", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nozaki, Aya"}], "nameIdentifiers": [{"nameIdentifier": "2954", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ito, Ayako"}], "nameIdentifiers": [{"nameIdentifier": "2955", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Horie, Ichiro"}], "nameIdentifiers": [{"nameIdentifier": "2956", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Imaizumi, Misa"}], "nameIdentifiers": [{"nameIdentifier": "2957", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Usa, Toshiro"}], "nameIdentifiers": [{"nameIdentifier": "2958", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kawakami, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "2959", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-18"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "ActMed63_71.pdf", "filesize": [{"value": "723.5 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 723500.0, "url": {"label": "ActMed63_71.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/570/files/ActMed63_71.pdf"}, "version_id": "eebea0bf-6d2f-427f-89bc-1eea31260b22"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "differentiated thyroid carcinoma", "subitem_subject_scheme": "Other"}, {"subitem_subject": "lenvatinib", "subitem_subject_scheme": "Other"}, {"subitem_subject": "prognosis", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Age, Symptomatic Metastatic Disease, and Malignant Pleural Effusion as Predictors of Poor Prognosis in Patients with Differentiated Thyroid Carcinoma Treated with Lenvatinib.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Age, Symptomatic Metastatic Disease, and Malignant Pleural Effusion as Predictors of Poor Prognosis in Patients with Differentiated Thyroid Carcinoma Treated with Lenvatinib."}]}, "item_type_id": "3", "owner": "2", "path": ["92"], "permalink_uri": "http://hdl.handle.net/10069/39740", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-03-27"}, "publish_date": "2020-03-27", "publish_status": "0", "recid": "570", "relation": {}, "relation_version_is_last": true, "title": ["Age, Symptomatic Metastatic Disease, and Malignant Pleural Effusion as Predictors of Poor Prognosis in Patients with Differentiated Thyroid Carcinoma Treated with Lenvatinib."], "weko_shared_id": 2}
Age, Symptomatic Metastatic Disease, and Malignant Pleural Effusion as Predictors of Poor Prognosis in Patients with Differentiated Thyroid Carcinoma Treated with Lenvatinib.
http://hdl.handle.net/10069/39740
http://hdl.handle.net/10069/39740b0d1559c-a85e-4dd4-b63c-922085ed3c01
名前 / ファイル | ライセンス | アクション |
---|---|---|
ActMed63_71.pdf (723.5 kB)
|
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-03-27 | |||||
タイトル | ||||||
タイトル | Age, Symptomatic Metastatic Disease, and Malignant Pleural Effusion as Predictors of Poor Prognosis in Patients with Differentiated Thyroid Carcinoma Treated with Lenvatinib. | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | differentiated thyroid carcinoma | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | lenvatinib | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | prognosis | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | departmental bulletin paper | |||||
著者 |
Nakashima, Yomi
× Nakashima, Yomi× Ando, Takao× Nozaki, Aya× Ito, Ayako× Horie, Ichiro× Imaizumi, Misa× Usa, Toshiro× Kawakami, Atsushi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background: Lenvatinib is one of the few therapeutic options available for radioiodine-refractory thyroid cancer. However, the factors that determine the therapeutic outcomes remain unknown. Methods: Patients with thyroid carcinoma treated with lenvatinib who had been dead or who had survived for longer than a halfyear were retrospectively compared. We evaluated the clinical parameters when lenvatinib was started, and also studied the tumor volume reduction ratio, the duration until re-growth of the largest metastatic lesion, the thyroglobulin (Tg) reduction rate,and the duration until re-elevation of Tg after lenvatinib between survivors and dead patients.Results: We identified 16 patients, with an average age of 73.1±7.6 yrs and a male-to-female ratio of 5 to 11, who had advanced differentiated thyroid cancer that was treated with lenvatinib. Nine patients had died after 8.9±6.1 months, whereas 7 survived for 13.0±2.0 months after starting lenvatinib. The patients who died were older than the survivors (76.7±6.5 vs. 68.6±6.6 yrs, p=0.03).Malignant pleural effusion (p=0.017) and symptomatic metastatic disease (SMD) (p=0.039) were associated with death in a Kaplan-Meier survival analysis. Age (p=0.012, HR 1.150, CI 1.030-1.320) and SMD (p=0.014, HR 8.069, CI 1.503-61.34) were associated with poor outcome in a multivariate Cox proportional hazard model. The duration until the re-elevation of Tg was longer in survivors than in patients who died (6.43±4.55 vs. 2.17±1.39 months, p=0.025).Conclusions: We identified multiple factors, including SMD, that were related to poor outcomes after lenvatinib treatment. This study suggests that lenvatinib might be started before patients develop SMD. |
|||||
書誌情報 |
Acta medica Nagasakiensia 巻 63, 号 2, p. 71-77, 発行日 2020-03 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 00016055 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA00508430 | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
出版者 | ||||||
出版者 | Nagasaki University School of Medicine | |||||
出版者別言語 | ||||||
長崎大学医学部 | ||||||
sortkey | ||||||
03 | ||||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Acta medica Nagasakiensia, 63(2), pp.71-77; 2020 |